To Whom It May Concern:
I have reviewed the Gemiini language development program with clinical and basic neuroscience researchers in my department. While some of techniques and theories Laura Kasbar has developed are based only on empirical observations, my faculty and I believe that the Gemiini program has considerable promise for enhancing language ability for a number of different communication disorders.
If the Gemiini system works as we think it might, it will represent a significant advance for teaching language to special needs children. As one who has worked in the field of Down syndrome for many years, it is my hope that the Gemiini program would prove effective for those children as well.
My department would like to conduct a large-scale, 100-child, placebo-controlled clinical study to test Gemiini’s effectiveness for teaching a variety of special-needs children, including ESL (foreign language students), early talkers, Down Syndrome, and language delayed children. To ensure that we use an optimized study design, we intend to start with a smaller pilot study in which 20 of the most difficult to teach children, including those who have stalled in their current therapy program, are treated for 2 weeks. This smaller study will cost approximately $25,000 and I have committed to pay for it. The full-scale trial would cost approximately $150,000 to $250,000 to complete and will require additional sources of support. Importantly, it would be designed to meet the standards of the most rigorous clinical science, to be published in highly regarded peer-reviewed journals, and to stand up to the scrutiny of the lay press that would be expected if the study is successful.
I would be pleased to discuss our plans, and the parameters and costs of these trials with any party with a serious interest in contributing to the work.
William C. Mobley, M.D., Ph.D.
Chair and Distinguished Professor of Neurosciences
Florence Riford Chair for Alzheimer Disease Research